Revolution Medicines, Inc. (RVMD)

The past six months have seen significant volatility in Revolution Medicines' stock price due to acquisition speculation and clinical development updates. RBC Capital initiated coverage with an "Outperform" recommendation in November 2025, and the stock reached an all-time high of $72.76. In December 2025, the first patient was randomized in the RASolute 304 clinical trial of Daraxonrasib. January 2026 saw a surge in stock price due to acquisition rumors from AbbVie and Merck, with the stock reaching an all-time high closing price of $123.27 on January 15, 2026. However, AbbVie and Merck later denied these reports, causing the stock to drop. The company also announced FDA Breakthrough Therapy Designation for Zoldonrasib and dosed the first patient in a clinical trial evaluating RMC-5127. Revolution Medicines reported its third-quarter 2024 financial results and provided a pipeline update. As of February 6, 2026, the stock price was $97.49, with a 52-week range between $29.17 and $124.49.

As a clinical-stage biopharmaceutical company, Revolution Medicines does not have commercialized products and therefore does not experience traditional product demand seasonality. Its demand is primarily for its research and development capabilities, clinical trial enrollment, and funding to advance its pipeline. This demand is driven by the unmet medical need in RAS-addicted cancers, clinical trial progress and data, and strategic partnerships and funding.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on discovering and developing targeted therapies for cancers driven by the RAS and mTOR pathways. The company aims to transform cancer treatment by pioneering novel combination and monotherapy regimens. Revolution Medicines leverages a proprietary R&D platform to identify and optimize small molecules targeting difficult-to-drug cancer pathways. The company's pipeline includes RAS(ON) inhibitors like Daraxonrasib, Elironrasib G12C, and Zoldonrasib G12D, as well as RAS companion inhibitors like RMC-4630, RMC-5552, and RMC-5845. As a clinical-stage company, Revolution Medicines does not currently generate revenue from product sales.

Revolution Medicines, Inc. is headquartered in Redwood City, California. The company's primary operations are focused on research and development, with clinical trials potentially having a broader reach. Revolution Medicines is building out global commercial infrastructure, with appointments of regional General Managers for the U.S. and Europe in late 2025, signaling a future global presence for potential product launches.

Revolution Medicines maintains a strong scientific reputation within the precision oncology field for its innovative approach to targeting RAS-addicted cancers. The company's reputation has been significantly impacted by Breakthrough Therapy Designations for its RAS(ON) inhibitors, acquisition rumors with major pharmaceutical companies, and ongoing advancements in its clinical trials.

Revolution Medicines, Inc. is a publicly traded company with ownership widely distributed but heavily influenced by institutional investors. Institutional investors hold a significant majority of the company's stock. Major institutional shareholders include Vanguard Group Inc, Farallon Capital Management Llc, Janus Henderson Group Plc, Wellington Management Group Llp, Baker Bros. Advisors Lp, Fmr Llc, BlackRock, Inc., Nextech Invest, Ltd., Paradigm Biocapital Advisors LP, and Bellevue Group AG. Insider ownership is reported to be around 6.19% or 2.23%, with CEO Mark A. Goldsmith directly owning 0.4% of the company's shares. Retail investor ownership is reported to be around 5.39% or 62.85%, with Andrew J.M. Spokes owning the most shares among individual investors.